A Missense Mutation rs781536408 (c.2395G>A) of TYK2 Affects Splicing and Causes Skipping of Exon18 in vivo

Suqing Chen1, Peilin Wu1*, Bin Wu1, Chenye Lin1, Junhong Chen1, Lishengdan Chen1 and Ge Lv2

1Department of Pediatrics, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China, 2Chongqing Key Laboratory of Child Infectious and Immunity, Children’s Hospital of Chongqing Medical University, Chongqing, China

TYK2 variants can impact disease onset or progression. In our previous study, we identified abnormal splicing that happened near rs781536408 in the TYK2 gene. The purpose of this research was to examine the effect of the mutation on alternative splicing in vivo and in vitro. Whole exome sequencing was performed to identify the mutations followed by bidirectional Sanger sequencing. Then the minigene analysis was carried out based on HeLa and HEK293T cell lines. The results showed that rs781536408 (c.2395G>A, p.G799R) was homozygous in the patient, but heterozygous in parents. PCR amplification confirmed the abnormal splicing in the somatic cells of the patients, but not in the parents. Sanger sequencing results showed that there was a skipping of exon18 near the mutation. For minigene analysis, there was no difference between the wild-type and the mutant type in the two minigene construction strategies, indicating that mutation c.2395G>A had no effect on splicing in vitro. Combining the results of in vivo, we speculated that the effect of the mutation on splicing was not absolute, but rather in degree.

Keywords: TYK2, mutation, splicing, minigene, mRNA

INTRODUCTION

RNA splicing is a process that enables a pre-mRNA to mature mRNA by removing introns and joining together exons. Alternative splicing can be induced by single-nucleotide polymorphism (SNP). Most genes in human beings produce multiple transcript variants due to alternative splicing (Modrek and Lee, 2002). However, the correct pattern of splicing does not always happen. Some splicing errors may lead to diseases (Fernandez Alanis et al., 2012), such as growth hormone deficiency (GHD), spinal muscular atrophy (SMA), and neurodegeneration. There are many reasons for abnormal splicing, among which SNP mutation is an important one. As previously reported, mutations in exon splicing enhancers could induce abnormal transcript formation, affect protein coding, and further make people sick (Blencowe, 2006; Graveley, 2000).
**TYK2** is one of the JAK protein tyrosine kinase family members. **TYK2** mediates the signaling of many antivirals and immunoregulatory cytokines, such as type I and type III IFNs, IL-10, IL-12, IL-22, and IL-23 (Li et al., 2020). However, the effects of **TYK2** mutation on the pathogenesis or progression of the diseases are still in suspense. On the **TYK2** locus, there were over 500 SNPs that can cause non-synonymous encoding. Among them, rs781536408 (c.2395G>A) is a lower-frequency mutation. Besides our previous report (Wu et al., 2020), no other studies have reported on this mutation. As a non-synonymous mutation, rs781536408 may change the structure of Tyk2 protein and may even inactivate Tyk2 protein. For its function, more work is needed for verification.

Single-nucleotide polymorphisms can affect mRNA splicing, nucleocytoplasmic export, RNA stability, and translation. When SNP changed the codon and causes amino acids to change, the protein activity may even be affected (Rodriguez-Martínez et al., 2020).

In this study, we found that the **TYK2** gene can undergo abnormal splicing near rs781536408. So we hypothesized that rs781536408 might be a splicing-relevant mutation. This study aimed to explore the effect of the mutation on alternative splicing in vivo and in vitro. Therefore, we attempt to clarify the potential molecular mechanism of the relationship between **TYK2** transcripts and the rs781536408 mutation.

### MATERIALS AND METHODS

**Clinical Examination and Sample Collection**

This present study was licensed by the Ethics Committee of The First Affiliated Hospital of Fujian Medical University [ID: MRCTA, ECFAH of FMU (2019)218]. Written informed consent was obtained from all participants. Blood samples were sampled and stored at −80°C. Collection of The First Affiliated Hospital of Fujian Medical University (Rodríguez-Martínez et al., 2020). Written informed consent was obtained from all participants. Blood samples were sampled and stored at −80°C. The extraction and purification of DNA and RNA were carried out using an ALLPrep DNA/RNA/miRNA Universal Kit (Qiagen, Hilden, Germany) following the manufacturer’s instructions. The quality control of the purified nucleic acid was performed using the ND-1000 NanoDrop (Thermo Fisher Scientific, Wilmington, DE, United States).

**Whole Exome Sequencing and Analysis**

Firstly, genomic DNA was randomly sonicated to generate 150–200-bp products. Then, the sequencing libraries were prepared using the Lybay DNA Library Prep Kit for Illumia (Lybaybio, Tianjin, China). DNA libraries were hybridized to obtain the exon sequence using Lybay Human exon capture Kit (Lybaybio, Tianjin, China). The whole exon sequencing data were generated, processed, and analyzed by Allwgene Technology Co., Ltd. (Beijing, China). The libraries were sequenced by an Illumina HiSeq4000 platform under the paired-end 150-bp mode. The data were filtered using FastQC (version 0.11.9) with default parameters. We aligned the sequenced reads to the human reference genome (GRCh37/hg 19) by Burrows-Wheeler Aligner (BWA, version 0.6.2) and filtered the duplicates using SAMtools (version 1.2), by analyzing the type of mutation sites in the family and comparing and screening the mutation sites that are most likely to cause disease based on the dbSNP, 1000 Genomes Project, and ExAC databases.

**Sanger Sequencing**

The screening for **TYK2** mutation was conducted by bidirectional Sanger sequencing. Gene-specific PCR primers were designed and used to amplify sequences applying standard PCR amplification protocols. Briefly, the PCR products were amplified by ExoSAP-IT method (USB, Cleveland, OH, United States). Then, the products were sequenced using Big Dye Termination Chemistry [Applied Biosystems (ABI), Weiterstadt, Germany] and separated on a DNA capillary sequencer (ABI 3100 genetic analyzer; ABI, Weiterstadt, Germany).

**Plasmid Construction**

The minigene construct was generated by gene synthesis (Sangon, Shanghai, China). Two plasmids, pEGFP-C1 and pcMINI-N, were used in the experiment. The mutant (mut) and wild-type (WT) were reconstructed with pEGFP-C1 and pcMINI-N. The reaction system is similar to that the previous report (Rodriguez-Martinez et al., 2020). The recombinant vectors were transiently transfected into HeLa and HEK293T cell lines (American Type Culture Collection, Manassas, VA, United States). The transfection method was carried out according to the liposome 3000 (Thermo Fisher Scientific, Waltham, MA, United States) following the manufacturer’s instruction, and cell samples were collected at the 48th hour. Then, the total RNA in these cells was extracted and the primers on both sides of minigene was used to carry out PCR amplification, using agarose gel to detect the gene transcription band size. The clones’ sequence was confirmed by Sanger sequencing. Primers used for cloning and final DNA sequences are listed in Supplementary Table 1.

**Splicing Prediction**

Splicing prediction of WT and mut sequences was conducted using Human Splicing Finder (HSF1), MutationTaster2, SpliceAI1, Spliceogen4, and MMSplice5 with the Default parameters.

**Quantitative Real-time PCR Analysis**

The expression of transcript was quantified by qRT-PCR using a TransScript Green two-step qRT-PCR Supermix kit (TransGen Biotech, Beijing, China) according to the manufacturer’s instructions. Expression of the housekeeping gene β-acting was used as an internal control for normalization. The PCR amplification cycle conditions were 50°C for 2 min, 94°C for 10 min, 95°C for 15 s, and 60°C for 1 min for 40 cycles. The relative expression of the target gene was determined using the Ct (2−ΔΔCT) method. The sequences of the primers are listed in Supplementary Table 1.

---

1. [www.umd.be/hsf3](http://www.umd.be/hsf3)
2. [http://www.mutationtaster.org](http://www.mutationtaster.org)
3. [https://spliceailookup.broadinstitute.org](https://spliceailookup.broadinstitute.org)
4. [https://github.com/VCCRI/Spliceogen](https://github.com/VCCRI/Spliceogen)
5. [https://github.com/gagneurlab/MMSplice](https://github.com/gagneurlab/MMSplice)
RESULTS

Identification of c.2395G>A Mutation in TYK2 Gene

From the exome sequencing data of all the three family members recruited in the study, only one homozygous mutation was identified in the patient (this mutation is heterozygous in the patient's parents). This homozygous mutation p.G799R (c.2395G>A) was identified in the TYK2 gene in the patient (Figure 1A). This mutation (rs781536408) was also reported in GnomAD, TOPMED, and ExAC databases with a frequency of 0.000020, 0.000016, and 0.000009, respectively. The mutation was confirmed in all the family members by Sanger sequencing (Figure 1B). By analyzing the amino acid sequence changes caused by p.G799R mutations in different species, we found that the mutated glycine residue in p.G799R was not evolutionarily conserved (Figure 1C). The four bases upstream (5') of the mutation site are GTGG, which may be a variable splicing recognition site. The clinical features and phenotypes of the patient showed symptoms such as pneumonia, enteritis, and autism [the case report has been published with the consent of his family (Wu et al., 2020)].

Bioinformatics Prediction of Variable Splicing Site Caused by c.2395G>A Mutation

The pathogenicity of the c.2395G>A mutation is supported by in silico analyses using two different programs: HSF (see text footnote 1) and MutationTaster (see text footnote 2). HSF prediction results showed that the c.2395G>A mutation led to the activation of a new intron splice acceptor site, and the sequence of the intron–exon boundary is gacaagggagGT, which might produce three exon splice suppressors (ESSs). MutationTaster predicted that a new donor site was formed, and its exon–intron boundary sequence was ACAT-gttg. Also, the prediction information of the other databases also confirmed it. The details of the prediction results of SpliceAI, Spliceogen, and MMSplice are shown in Supplementary Table 2.

![Figure 1](https://www.ncbi.nlm.nih.gov/variation/view/?q=rs781536408)
Transcription Experimental Analysis Revealed a Different Splicing Pattern Near the Genomic Location of TYK2 Mutation

To compare the transcriptional differences between heterozygous and homozygous mutations, RT-PCR followed by Sanger sequencing was performed. The agarose gel electrophoresis of PCR products results showed that both parents of the patient had only one PCR band, while the patient had two (Figure 2A). In order to improve the detection sensitivity, we designed two pairs of specific primers according to the sequence of band a and band b for qRT-PCR detection (primers a and b correspond to band a and band b, respectively). The expression of band a in the patient was about 70% of that in the parents (Figure 2B). In addition, the signal of band b was only found in the patient, not in the parents (Figure 2C). The Sanger sequencing results confirmed that there was only a normal splicing pattern found in the parents [Exon14 (47 bp)–Exon15 (128 bp)–Exon16 (136 bp)–Exon17 (155 bp)–Exon18 (151 bp)–Exon19 (65 bp)]. However, in addition to the normal form of splicing, a novel variable splice form was found in the patient [Exon14 (47 bp)–Exon15 (128 bp)–Exon16 (136 bp)–ΔExon17 (78 bp)–Exon19 (65 bp); Figures 2D,E]. The Sanger sequencing results showed that the novel alternative splicing occurred at the fourth base upstream (5') of the mutation site with the exon–intron boundary sequence ACAAG-tggg, indicating the partial absence of Exon17 and the skipping of Exon18 (Figure 2D). This boundary was the same as predicted by the MutationTaster.

Effect of c.2395G>A Mutation on Alternative Splicing in vitro

To determine whether c.2395G>A disrupted splicing of TYK2, the entire genomic region spanning from TYK2 Exon16 to Exon17 was cloned into pEGFP-C1-TYK2-wt/mut and expressed as minigenes in human 293T and HeLa cells. The results showed that there is only one PCR band with the same size for both WT and mut type in both 293T and HeLa (Figure 3). The Sanger sequencing results showed that this band was Exon16 (136 bp)–Intron16 (84 bp)–Exon17 (155 bp); no other forms of splicing occurred (Figure 3). In addition, the complete Exon16 (136 bp), Exon17 (155 bp), Intron16 (84 bp), and part of Intron17 (480 bp) sequences were inserted into the pcMINI-N vector to construct the pcMINI-N-TYK2-wt/mut recombinant vector, which contained a universal MSC-IntronB-ExonB sequence. The PCR results showed two PCR bands (bands a and b, Figure 4). Sequencing results showed that band a was a regular splicing band [Exon16 (136 bp)–Exon17 (155 bp)–ExonB, Figure 4]; band b spliced the complete Exon17 [Exon16 (136 bp)–ExonB, Figure 4]. In summary, there was no difference between the WT and the mut type in the two minigene construction strategies, indicating that mutation c.2395G>A did not affect splicing in vitro.

DISCUSSION

TYK2 is one of the JAK protein tyrosine kinase family members that associate with the receptors like the type I IFN receptor (IFNAR), IL-10 family receptors (IL-10R and IL-22R), and IL-12 family receptors (IL-12R and IL-23R) (Strobl et al., 2011). People naturally deficient in TYK2 have increased sensitivity to mycobacterial and viral infections (Kreins et al., 2015; Fuchs et al., 2016). Based on this patient, our previous studies found that the expression levels of Tyk2 protein and gene were decreased by c.2395G>A mutation (Wu et al., 2020), so his susceptibility to mycobacterial and viral infections was well explained. This mutation caused the decrease of protein content and caused the occurrence of variable splicing in the patient. We found that the substitution amino acid induced by c.2395G>A does alter TYK2 function through bioinformatic prediction. According to our previous study (Wu et al., 2020), there was no expressed TYK2 protein detected in the patient with homozygous mutation, indicating that it would be loss-of-function, in which case the patient is likely ill because of homozygosity for the missense protein. In addition, the expression of band a in the patient was about 70% of that in the parents, but no TYK2 protein was detected, indicating that the possible cause of the disease is due to the substitution of amino acids, which might lead to protein inactivation or incomplete synthesis. We did not detect band b in the parental samples, which might be caused by the dominant effect or epistatic effect of alleles. As we know, most genetic traits are much more complex than a simple dominant/recessive relationship; therefore, there might be other ways to inhibit the expression of splicing in heterozygotes. Hence, more experiments were needed to reveal the mechanism. For the splicing of TYK2, the actual variable splicing start site is consistent with that predicted by the MutationTaster, indicating that it is a donor site. This alternative splicing pattern complied with the GT-AG rule (Burset et al., 2000). Previous reports showed that alternations near intron boundaries or cis-splicing regulatory elements could change the efficiency or patterns of splicing (Lee and Rio, 2015; Ramanouskaya and Grinev, 2017). The consensus sequence is ACAAG-tggg, with the GT after CAA as the donor site, similar to Ohno’s reports (Ohno et al., 2018). The last two bases of exons are highly conserved as AG in 80% of 50 splice sites (Demirci et al., 2004). This mutation in our present results could probably disrupt the exon–intron junction.

However, the puzzle is that there was no difference between the WT and the mut type in the two minigene construction strategies. Combined with the results of in vivo, we speculated that the effect of the mutation on splicing was not absolute but instead in degree. According to the gray scale of the two PCR bands, this site might have a weak influence on splicing. So this may be the reason for the negative result of minigene in vitro. Due to the limitation of minigene technology, it is impossible to insert the whole sequence from Exon17 to Exon19 (the sequence is too long to insert), which might be the fundamental reason for the absence of an alternative splicing pattern in vitro.

Many studies have reported on genetic variants that modulate pre-mRNA splicing and in turn influence phenotype and disease risk (Li et al., 2016; Manning and Cooper, 2017; Park et al., 2018).
Chen et al. Mutation of TYK2 Affects Splicing

FIGURE 2 | C.2395G>A mutation caused different splicing patterns in the family. (A) Agarose gel electrophoresis. Band a and band b represent normal splicing and abnormal splicing, respectively. M means the DNA marker. (B) The qRT-PCR results of band a; *p < 0.05. (C) The qRT-PCR results of band b; *p < 0.05. (D,E) The schematic representation and the Sanger sequencing results of the two different transcripts.

These studies have a wide range of implications, because they can reveal the pathogenesis of diseases and provide information for the treatment options of diseases (Nielsen et al., 2007; Gregory et al., 2012; Ng et al., 2012; Matesanz et al., 2015). Pre-mRNA splicing is a highly regulated process. Each exon is controlled by a combination of flanking splicing sites and multiple splicing regulatory elements. These elements can exist in exon and intron sequences and are not easy to be identified by sequence (Li et al., 2020). Usually, they act as binding platforms for splicing regulators (such as Tyk2 protein) and can promote exon inclusion (enhancer) or cause exon jumping (silencer).

DATA AVAILABILITY STATEMENT

The data presented in the study are deposited in the Genome Sequence Archive for Human (GSA-Human) repository, accession number HRA000803.
ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Ethics Committee of The First Affiliated Hospital of Fujian Medical University [ID: MRCTA, ECFAH of FMU (2019)218]. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin.

AUTHOR CONTRIBUTIONS

SC and PW substantially contributed to the conception and design of the work, drafted the work and revised it critically for important intellectual content. BW and CL completed the clinical examination and sample collection. LC, CL, JC, and GL helped perform the experiments and analyzed the data. BW and SC involved in the analysis and interpretation of data for the work. PW agreed to be accountable for the work in ensuring that questions related to the integrity of any part of the work are appropriately investigated and resolved. All authors read and approved the final manuscript.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2021.679678/full#supplementary-material

Supplementary Table 1 | Primer sequence information.
Supplementary Table 2 | Database prediction information.
REFERENCES

Blencowe, B. J. (2000). Exonic splicing enhancers: mechanism of action, diversity and role in human genetic diseases. Trends Biochem. Sci. 25, 106–110. doi: 10.1016/s0968-0004(00)51549-8

Burset, M., Seledsova, I. A., and Solovyev, V. V. (2000). Analysis of canonical and non-canonical splice sites in mammalian genomes. Nucleic Acids Res. 28, 4364–4375. doi: 10.1093/10.4.21.4364

Demirci, F. Y., Radak, A. I., Rigatti, B. W., Mah, T. S., and Gorin, M. B. (2004). A presumed missense mutation of RPGR causes abnormal RNA splicing with exon skipping. Am. J. Ophthalmol. 138, 504–505. doi: 10.1016/j.ajo.2004.04.019

Fernandez Alanis, A., Pinotti, M., Dal Mas, A., Balestra, D., Cavallari, N., Rogalska, M. E., et al. (2012). An exon-specific U1 small nuclear RNA (snRNA) strategy to correct splicing defects. Hum. Mol. Genet. 21, 2389–2398. doi: 10.1093/hmg/ddq045

Fuchs, S., Kaiser-Labusch, P., Bank, J., Ammann, S., Kolb-Kokocinski, A., Edelbusch, C., et al. (2016). Tyrosine kinase 2 is not limiting human antiviral type III interferon responses. Eur. J. Immunol. 46, 2639–2649. doi: 10.1002/eji.201646519

Graveley, B. R. (2000). Sorting out the complexity of SR protein functions. RNA 6, 1197–1211. doi: 10.1017/s135583820000960

Gregory, A. P., Dendrou, C. A., Attfield, K. E., Haghiakia, A., Xifara, D. K., Butter, F., et al. (2012). TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature 488, 508–511. doi: 10.1038/nature11307

Kreins, A. Y., Ciancanelli, M. J., Okada, S., Kong, X. F., Ramirez-Alejo, N., Kilic, S. S., et al. (2015). Human TYK2 deficiency: mycobacterial and viral infections without hyper-IgE syndrome. J. Exp. Med. 201646519

Lee, Y., and Rio, D. C. (2015). Mechanisms and regulation of alternative pre-mRNA splicing. Annu. Rev. Biochem. 84, 291–323.

Li, Y. I., van de Geijn, B., Raj, A., Knowles, D. A., Petti, A. A., Golan, D., et al. (2016). RNA splicing is a primary link between genetic variation and disease. Science 352, 600–604. doi: 10.1126/science.aad9417

Li, Z., Rotival, M., Patin, E., Michel, F., and Pellegrini, S. (2020). Two common disease-associated TYK2 variants impact exon splicing and TYK2 dosage. PLoS One 15:e0225289. doi: 10.1371/journal.pone.0225289

Manning, K. S., and Cooper, T. A. (2017). The roles of RNA processing in translating genotype to phenotype. Nat. Rev. Mol. Cell Biol. 18, 102–114. doi: 10.1038/nrm.2016.139

Matesanz, F., Potencion, V., Fedetz, M., Ramos-Mozo, P., Abad-Grau Mdel, M., Karaky, M., et al. (2015). A functional variant that affects exon-skipping and protein expression of SP140 as genetic mechanism predisposing to multiple sclerosis. Hum. Mol. Genet. 24, 5619–5627. doi: 10.1093/hmg/ddv256

Modrek, B., and Lee, C. (2002). A genomic view of alternative splicing. Nat. Genet. 30, 13–19. doi: 10.1038/ng1002-13

Ng, K. P., Hillmer, A. M., Chiuah, C. T., Juan, W. C., Ko, T. K., Teo, A. S., et al. (2012). A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat. Med. 18, 521–528.

Nielsen, K. B., Sorensen, S., Cartegni, L., Corydon, T. J., Doktor, T. K., Schroeder, L. D., et al. (2007). Seemingly neutral polymorphic variants may confer immunity to splicing-inactivating mutations: a synonymous SNP in exon 5 of MCAD protects from deleterious mutations in a flanking exonic splicing enhancer. Am. J. Hum. Genet. 80, 416–432. doi: 10.1086/51992

Ohno, K., Takeda, J. I., and Masuda, A. (2018). Rules and tools to predict the splicing effects of exonic and intronic mutations. Wiley Interdiscip. Rev. RNA 9:e1451. doi: 10.1002/wrna.1451

Park, E., Pan, Z., Zhang, Z., Lin, L., and Xing, Y. (2018). The expanding landscape of alternative splicing variation in human populations. Am. J. Hum. Genet. 102, 11–26. doi: 10.1016/j.ajhg.2017.11.002

Ramanouskaya, T. V., and Grinev, V. V. (2017). The determinants of alternative RNA splicing in human cells. Mol. Genet. Genomics 292, 1175–1195. doi: 10.1007/s00438-017-1350-0

Rodriguez-Martinez, M., Boissière, T., Noe Gonzalez, M., Litchfield, K., Mitter, R., Walker, J., et al. (2020). Evidence that STK19 is not an NRAS-dependent melanoma driver. Cell 181, 1395–1405.e11.

Strobl, B., Stoiber, D., Seel, V., and Mueller, M. (2011). Tyrosine kinase 2 (TYK2) in cytokine signalling and host immunity. Front. Biosci. 16, 3214–3232. doi: 10.2741/3908

Wu, P., Chen, S., Wu, B., Chen, J., and Lv, G. (2020). A TYK2 gene mutation c.2395G>A leads to TYK2 deficiency: a case report and literature review. Front. Pediatr. 8:253. doi: 10.3389/fped.2020.00253

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Chen, Wu, Wu, Lin, Chen, Chen and Lv. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.